Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero
- PMID: 16504990
- PMCID: PMC1798357
- DOI: 10.1136/ard.2005.049866
Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero
Abstract
Background: Antenatal and postnatal treatment with dexamethasone (DEX) may negatively affect the neuropsychological development in children. Maternal anti-Ro/Sjögren's syndrome A (SSA) antibodies may also be associated with learning disabilities in offspring.
Objective: To assess neuropsychological development in babies exposed to very high dosages of DEX in utero, whose mothers were anti-Ro/SSA positive.
Methods: 13 children with congenital complete heart block (CHB) (11 exposed and 2 not exposed to DEX) and 3 healthy siblings, all of anti-Ro/SSA-positive women, were evaluated. 11 preschool-aged children (5 boys) were assessed using Griffiths Mental Development Scales. 5 school-aged children (2 boys) were examined using Wechsler Intelligence Scale for Children-Revised to check IQ and reading tests to explore the existence of learning disabilities or dyslexia. None of the children had had major neonatal complications, although those with CHB had to be paced at different intervals from birth.
Results: The children had been exposed in utero to a mean total dose of 186.6 mg DEX. IQ levels were always normal (mean IQ 105.1, standard deviation (SD) 9.5). Only one child had a learning disability, of borderline clinical significance, but this child had never been exposed to DEX.
Conclusion: No negative effects were found on the neuropsychological development in this cohort of children, even if they had been exposed to maternal anti-Ro/SSA antibodies and to very high dosages of DEX (much higher than those used to improve fetal lung maturity). These findings might be of interest in view of the large number of infants exposed in the past to repeated antenatal courses of steroids.
Conflict of interest statement
Competing interests: None.
Similar articles
-
Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children.Arthritis Rheumatol. 2014 Aug;66(8):2290-6. doi: 10.1002/art.38675. Arthritis Rheumatol. 2014. PMID: 24756962
-
Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero.Ann Rheum Dis. 2019 May;78(5):696-703. doi: 10.1136/annrheumdis-2018-214406. Epub 2019 Feb 26. Ann Rheum Dis. 2019. PMID: 30808622
-
Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern.Ann Rheum Dis. 2012 Mar;71(3):334-40. doi: 10.1136/annrheumdis-2011-200207. Epub 2011 Sep 27. Ann Rheum Dis. 2012. PMID: 21953338
-
Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature.Am J Reprod Immunol. 1999 Oct;42(4):226-32. doi: 10.1111/j.1600-0897.1999.tb00095.x. Am J Reprod Immunol. 1999. PMID: 10580604 Review.
-
[Congenital heart block associated with maternal anti SSA/SSB antibodies :a report of four cases].Pathol Biol (Paris). 2004 Apr;52(3):138-47. doi: 10.1016/j.patbio.2003.06.002. Pathol Biol (Paris). 2004. PMID: 15063933 Review. French.
Cited by
-
Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.Clin Rev Allergy Immunol. 2011 Feb;40(1):27-41. doi: 10.1007/s12016-009-8190-6. Clin Rev Allergy Immunol. 2011. PMID: 20012231 Free PMC article. Review.
-
Atrioventricular block during fetal life.J Saudi Heart Assoc. 2015 Jul;27(3):164-78. doi: 10.1016/j.jsha.2014.07.001. Epub 2014 Jul 10. J Saudi Heart Assoc. 2015. PMID: 26136631 Free PMC article. Review.
-
Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis.Life (Basel). 2024 Feb 26;14(3):305. doi: 10.3390/life14030305. Life (Basel). 2024. PMID: 38541631 Free PMC article. Review.
-
Neonatal lupus erythematosus: an acquired autoimmune disease to be taken seriously.Ann Med. 2025 Dec;57(1):2476049. doi: 10.1080/07853890.2025.2476049. Epub 2025 Mar 11. Ann Med. 2025. PMID: 40066690 Free PMC article. Review.
-
Glucocorticoid use and varying doses on the long-term outcomes of offspring born to patients with systemic lupus erythematosus.Eur J Pediatr. 2024 May;183(5):2231-2238. doi: 10.1007/s00431-024-05462-1. Epub 2024 Feb 23. Eur J Pediatr. 2024. PMID: 38393371
References
-
- Huang W L, Haper C G, Evans S F, Newnham J P, Dunlop S A. Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep. Int J Dev Neurosci 200019487–493. - PubMed
-
- Matthews S G. Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res 200047291–300. - PubMed
-
- Jobe A H, Wada N, Berry L M, Ikegami M, Ervin M G. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol 1998178880–885. - PubMed
-
- French N P, Hagan R, Evans S F, Godfrey M, Newnham J P. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999180114–121. - PubMed
-
- Abbasi S, Hirsch D, Davis J, Tolosa J, Stouffer N, Debbs R. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 20001821243–1249. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous